Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: A review

Biomaterials

Volumn 85, Issue , 2016, Pages 152-167

  Kanamala, Manju ^a   Wilson, William R ^b   Yang, Mimi ^a   Palmer, Brian D ^b   Wu, Zimei ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Intracellular delivery; PEG detachment; PH sensitive bond; PH sensitive nanocarriers; Protonation; Tumour targeted drug delivery

Indexed keywords

CHEMOTHERAPY; ENZYME ACTIVITY; PH SENSORS; PROTONATION; TUMORS;

EFFICIENT DRUG DELIVERY; EXTRACELLULAR MICROENVIRONMENT; INTRACELLULAR DELIVERY; INTRACELLULAR ORGANELLE; NANO-CARRIERS; PH RESPONSIVE BIOMATERIALS; PH SENSITIVE; TARGETED DRUG DELIVERY;

PH;

ACETAL DERIVATIVE; AMIDE; BIOMATERIAL; ETHER DERIVATIVE; HYDRAZONE DERIVATIVE; IMINE; NANOCARRIER; OXIME DERIVATIVE; NANOMATERIAL;

CHEMICAL BOND; CONFORMATIONAL TRANSITION; DRUG DELIVERY SYSTEM; DRUG RELEASE; PH; PRIORITY JOURNAL; PROTON TRANSPORT; REVIEW; ANIMAL; CHEMISTRY; CLINICAL TRIAL (TOPIC); DISEASE MODEL; HUMAN; NANOTECHNOLOGY; NEOPLASMS; PROCEDURES;

ANIMALS; BIOCOMPATIBLE MATERIALS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; DRUG LIBERATION; HUMANS; HYDROGEN-ION CONCENTRATION; NANOSTRUCTURES; NANOTECHNOLOGY; NEOPLASMS;

EID: 84958167285     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2016.01.061     Document Type: Review

References (209)

1. Cao Y., DePinho R.A., Ernst M., Vousden K. Cancer research: past, present and future. Nat. Rev. Cancer 2011, 11:749-754.
2. Rothenberg M.L., Carbone D.P., Johnson D.H. Improving the evaluation of new cancer treatments: challenges and opportunities. Nat. Rev. Cancer 2003, 3:303-309.
3. Patel N.R., Pattni B.S., Abouzeid A.H., Torchilin V.P. Nanopreparations to overcome multidrug resistance in cancer. Adv. Drug Deliv. Rev. 2013, 65:1748-1762.
4. Pathania D., Millard M., Neamati N. Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism. Adv. Drug Deliv. Rev. 2009, 61:1250-1275.
5. Wicki A., Witzigmann D., Balasubramanian V., Huwyler J. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J. Control. Release 2015, 200:138-157.
6. Jhaveri A., Deshpande P., Torchilin V. Stimuli-sensitive nanopreparations for combination cancer therapy. J. Control. Release 2014, 190:352-370.
7. Kanapathipillai M., Brock A., Ingber D.E. Nanoparticle targeting of anti-cancer drugs that alter intracellular signaling or influence the tumor microenvironment. Adv. Drug Deliv. Rev. 2014, 79-80:107-118.
8. Markman J.L., Rekechenetskiy A., Holler E., Ljubimova J.Y. Nanomedicine therapeutic approaches to overcome cancer drug resistance. Adv. Drug Deliv. Rev. 2013, 65:1866-1879.
9. Kaasgaard T., Andresen T. Liposomal cancer therapy: exploiting tumor characteristics. Expert Opin. Drug. Deliv. 2010, 7:225-243.
10. Cui Y., Wu Z., Liu X., Ni R., Zhu X., Ma L., et al. Preparation, safety, pharmacokinetics and pharmacodynamics of liposomes containing Brucea Javanica Oil. AAPS Pharm. Sci. Tech. 2010, 11:878-884.
11. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986, 46:6387-6392.
12. Fukumura D., Duda D.G., Munn L.L., Jain R.K. Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation 2010, 17:206-225.
13. Torchilin V. Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. Eur. J. Pharm. Biopharm. 2009, 71:431-444.
14. Liu J., Huang Y., Kumar A., Tan A., Jin S., Mozhi A., et al. pH-sensitive nano-systems for drug delivery in cancer therapy. Biotechnol. Adv. 2014, 32:693-710.
15. Shen M., Huang Y., Han L., Qin J., Fang X., Wang J., et al. Multifunctional drug delivery system for targeting tumor and its acidic microenvironment. J. Control. Release 2012, 161:884-892.
16. Jiang T., Li Y.M., Lv Y., Cheng Y.J., He F., Zhuo R.X. Amphiphilic polycarbonate conjugates of doxorubicin with pH-sensitive hydrazone linker for controlled release. Colloids Surf. B Biointerfaces 2013, 111C:542-548.
17. Moghimi S.M., Hunter A.C., Murray J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 2001, 53:283-318.
18. Kierstead P.H., Okochi H., Venditto V.J., Chuong T.C., Kivimae S., Frechet J.M., et al. The effect of polymer backbone chemistry on the induction of the accelerated blood clearance in polymer modified liposomes. J. Control. Release 2015, 213:1-9.
19. Zhang W., Wang G., See E., Shaw J.P., Baguley B.C., Liu J., et al. Post-insertion of poloxamer 188 strengthened liposomal membrane and reduced drug irritancy and in vivo precipitation, superior to PEGylation. J. Control. Release 2015, 203:161-169.
20. Immordino M.L., Dosio F., Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomedicine 2006, 1:297-315.
21. Felber A.E., Dufresne M.-H., Leroux J.-C. pH-sensitive vesicles, polymeric micelles, and nanospheres prepared with polycarboxylates. Adv. Drug Deliv. Rev. 2012, 64:979-992.
22. Fleige E., Quadir M.A., Haag R. Stimuli-responsive polymeric nanocarriers for the controlled transport of active compounds: concepts and applications. Adv. Drug Deliv. Rev. 2012, 64:866-884.
23. Forgac M. Vacuolar ATPases: rotary proton pumps in physiology and pathophysiology. Nat. Rev. Mol. Cell Biol. 2007, 8:917-929.
24. Warburg O. On respiratory impairment in cancer cells. Science 1956, 124:269-270.
25. Wike-Hooley J.L., Haveman J., Reinhold H.S. The relevance of tumour pH to the treatment of malignant disease. Radiother. Oncol. 1984, 2:343-366.
26. Vaupel P., Kallinowski F., Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 1989, 49:6449-6465.
27. Denny W.A., Wilson W.R. Considerations for the design of nitrophenyl mustards as agents with selective toxicity for hypoxic tumor cells. J. Med. Chem. 1986, 29:879-887.
28. Griffiths J.R. Are cancer cells acidic?. Br. J. Cancer 1991, 64:425-427.
29. Gillies R.J., Raghunand N., Karczmar G.S., Bhujwalla Z.M. MRI of the tumor microenvironment. J. Magn. Reson. Imaging 2002, 16:430-450.
30. Madshus I.H. Regulation of intracellular pH in eukaryotic cells. Biochem. J. 1988, 250:1-8.
31. Cardone R.A., Casavola V., Reshkin S.J. The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis. Nat. Rev. Cancer 2005, 5:786-795.
32. Pouyssegur J., Dayan F., Mazure N.M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006, 441:437-443.
33. Parks S.K., Chiche J., Pouyssegur J. Disrupting proton dynamics and energy metabolism for cancer therapy. Nat. Rev. Cancer 2013, 13:611-623.
34. Helmlinger G., Yuan F., Dellian M., Jain R.K. Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat. Med. 1997, 3:177-182.
35. Liu Y., Wang W., Yang J., Zhou C., Sun J. pH-sensitive polymeric micelles triggered drug release for extracellular and intracellular drug targeting delivery. Asian J. Pharm. Sci. 2013, 8:159-167.
36. Danhier F., Feron O., Préat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control. Release 2010, 148:135-146.
37. Torchilin V. Nanotechnology for intracellular delivery and targeting. Nanotechnology in Drug Delivery 2009, 313-346. Springer, New York. M. de Villiers, P. Aramwit, G. Kwon (Eds.).
38. Onaca O., Enea R., Hughes D.W., Meier W. Stimuli-responsive polymersomes as nanocarriers for drug and gene delivery. Macromol. Biosci. 2009, 9:129-139.
39. Photos P.J., Bacakova L., Discher B., Bates F.S., Discher D.E. Polymer vesicles in vivo: correlations with PEG molecular weight. J. Control. Release 2003, 90:323-334.
40. Cheng J., Ji R., Gao S.-J., Du F.-S., Li Z.-C. Facile synthesis of acid-labile polymers with pendent ortho esters. Biomacromolecules 2012, 13:173-179.
41. Bellocq N.C., Pun S.H., Jensen G.S., Davis M.E. Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. Bioconjug. Chem. 2003, 14:1122-1132.
42. Li Z., Qiu L., Chen Q., Hao T., Qiao M., Zhao H., et al. pH-sensitive nanoparticles of poly(L-histidine)-poly(lactide-co-glycolide)-tocopheryl polyethylene glycol succinate for anti-tumor drug delivery. Acta Biomater. 2015, 11:137-150.
43. Xu H., Paxton J.W., Wu Z. Enhanced pH-responsiveness, cellular trafficking, cytotoxicity and long-circulation of PEGylated liposomes with post-insertion technique using Gemcitabine as a model drug. Pharm. Res. 2015, 32:2428-2438.
44. Yin Q., Shen J., Zhang Z., Yu H., Li Y. Reversal of multidrug resistance by stimuli-responsive drug delivery systems for therapy of tumor. Adv. Drug Deliv. Rev. 2013, 65:1699-1715.
45. Liu J., Huang Y., Kumar A., Tan A., Jin S., Mozhi A., et al. pH-Sensitive nano-systems for drug delivery in cancer therapy. Biotechnol. Adv. 2014, 32:693-710.
46. Ganta S., Devalapally H., Shahiwala A., Amiji M. A review of stimuli-responsive nanocarriers for drug and gene delivery. J. Control. Release 2008, 126:187-204.
47. Deng H., Liu J., Zhao X., Zhang Y., Liu J., Xu S., et al. PEG-b-PCL copolymer micelles with the ability of pH-controlled negative-to-positive charge reversal for intracellular delivery of doxorubicin. Biomacromolecules 2014, 15:4281-4292.
48. Zhao X., Liu P., Song Q., Gong N., Yang L., Wu W.D. Surface charge-reversible polyelectrolyte complex nanoparticles for hepatoma-targeting delivery of doxorubicin. J. Mater. Chem. B 2015, 3:6185-6193.
49. Xu J.X., Tang J.B., Zhao L.H., Shen Y.Q. Advances in the study of tumor pH-responsive polymeric micelles for cancer drug targeting delivery. Yao xue xue bao = Acta Pharm. Sin. 2009, 44:1328-1335.
50. Hatakeyama H., Ito E., Akita H., Oishi M., Nagasaki Y., Futaki S., et al. A pH-sensitive fusogenic peptide facilitates endosomal escape and greatly enhances the gene silencing of siRNA-containing nanoparticles in vitro and in vivo. J. Control. Release 2009, 139:127-132.
51. Remaut K., Lucas B., Braeckmans K., Demeester J., De Smedt S.C. Pegylation of liposomes favours the endosomal degradation of the delivered phosphodiester oligonucleotides. J. Control. Release 2007, 117:256-266.
52. Li Y., Liu R., Yang J., Shi Y., Ma G., Zhang Z., et al. Enhanced retention and anti-tumor efficacy of liposomes by changing their cellular uptake and pharmacokinetics behavior. Biomaterials 2015, 41:1-14.
53. Hatakeyama H., Akita H., Harashima H. The polyethyleneglycol dilemma: advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors. Biol. Pharm. Bull. 2013, 36:892-899.
54. Gao Z., Zhang L., Sun Y. Nanotechnology applied to overcome tumor drug resistance. J. Control. Release 2012, 162:45-55.
55. Ichihara M., Shimizu T., Imoto A., Hashiguchi Y., Uehara Y., Ishida T., et al. Anti-PEG IgM response against PEGylated liposomes in mice and rats. Pharmaceutics 2011, 3:1-11.
56. Yang Q., Ma Y., Zhao Y., She Z., Wang L., Li J., et al. Accelerated drug release and clearance of PEGylated epirubicin liposomes following repeated injections: a new challenge for sequential low-dose chemotherapy. Int. J. Nanomedicine 2013, 8:1257-1268.
57. Ishida T., Kiwada H. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int. J. Pharm. 2008, 354:56-62.
58. Ma H., Shiraishi K., Minowa T., Kawano K., Yokoyama M., Hattori Y., et al. Accelerated blood clearance was not Induced for a gadolinium-containing PEG-poly(L-lysine)-based polymeric micelle in mice. Pharm. Res. 2010, 27:296-302.
59. van den Hoven J.M., Nemes R., Metselaar J.M., Nuijen B., Beijnen J.H., Storm G., et al. Complement activation by PEGylated liposomes containing prednisolone. Eur. J. Pharm. Sci. 2013, 49:265-271.
60. Moein Moghimi S., Hamad I., Bunger R., Andresen T.L., Jorgensen K., Hunter A.C., et al. Activation of the human complement system by cholesterol-rich and PEGylated liposomes-modulation of cholesterol-rich liposome-mediated complement activation by elevated serum LDL and HDL levels. J. Liposome Res. 2006, 16:167-174.
61. Moghimi S.M., Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res. 2003, 42:463-478.
62. Moghimi S.M. Chemical camouflage of nanospheres with a poorly reactive surface: towards development of stealth and target-specific nanocarriers. BBA - Mol. Cell Res. 2002, 1590:131-139.
63. Moghimi S.M., Hamad I., Andresen T.L., Jorgensen K., Szebeni J. Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production. FASEB J. 2006, 20:2591-2593.
64. Hamad I., Al-Hanbali O., Hunter A.C., Rutt K.J., Andresen T.L., Moghimi S.M. Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere-serum interface: implications for stealth nanoparticle engineering. ACS Nano 2010, 4:6629-6638.
65. Moghimi S.M., Andersen A.J., Ahmadvand D., Wibroe P.P., Andresen T.L., Hunter A.C. Material properties in complement activation. Adv. Drug Deliv. Rev. 2011, 63:1000-1007.
66. Jager E., Jager A., Etrych T., Giacomelli F.C., Chytil P., Jigounov A., et al. Self-assembly of biodegradable copolyester and reactive HPMA-based polymers into nanoparticles as an alternative stealth drug delivery system. Soft Matter 2012, 8:9563-9575.
67. Grainger S.J., El-Sayed M.E. Stimuli-sensitive particles for drug delivery. Biolog. Responsive Hybrid Biomater. 2010, 171-190.
68. Reyes-Ortega F. 3-pH-responsive polymers: properties, synthesis and applications. Smart Polymers and Their Applications 2014, 45-92. Woodhead Publishing. M.R. Aguilar, J.S. Román (Eds.).
69. Simões S., Slepushkin V., Düzgünes N., Pedroso de Lima M.C. On the mechanisms of internalization and intracellular delivery mediated by pH-sensitive liposomes. BBA Biomembr. 2001, 1515:23-37.
70. Liu Y., Feng L., Liu T., Zhang L., Yao Y., Yu D., et al. Multifunctional pH-sensitive polymeric nanoparticles for theranostics evaluated experimentally in cancer. Nanoscale 2014, 6:3231-3242.
71. Wang L., Liu G., Wang X., Hu J., Zhang G., Liu S. Acid-disintegratable polymersomes of pH-responsive amphiphilic Diblock copolymers for intracellular drug delivery. Macromole 2015, 48:7262-7272.
72. Etrych T., Jelinkova M., Rihova B., Ulbrich K. New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties. J. Control. Release 2001, 73:89-102.
73. Fei L., Yap L.-P., Conti P.S., Shen W.-C., Zaro J.L. Tumor targeting of a cell penetrating peptide by fusing with a pH-sensitive histidine-glutamate co-oligopeptide. Biomaterials 2014, 35:4082-4087.
74. Kang X.-J., Dai Y.-L., Ma P.-A., Yang D.-M., Li C.-X., Hou Z.-Y., et al. Poly(acrylic acid)-modified Fe3O4 microspheres for magnetic-targeted and pH-triggered anticancer drug delivery. Chem. Eur. J. 2012, 18:15676-15682.
75. Ding D., Wang J., Zhu Z., Li R., Wu W., Liu B., et al. Tumor accumulation, penetration, and antitumor response of cisplatin-loaded gelatin/poly(acrylic acid) nanoparticles. ACS Appl. Mater. Interfaces 2012, 4:1838-1846.
76. Yan X., Gemeinhart R.A. Cisplatin delivery from poly(acrylic acid-co-methyl methacrylate) microparticles. J. Control. Release 2005, 106:198-208.
77. Bersani S., Vila-Caballer M., Brazzale C., Barattin M., Salmaso S. pH-sensitive stearoyl-PEG-poly(methacryloyl sulfadimethoxine) decorated liposomes for the delivery of gemcitabine to cancer cells. Eur. J. Pharm. Biopharm. 2014, 88:670-682.
78. Schmaljohann D. Thermo- and pH-responsive polymers in drug delivery. Adv. Drug Deliv. Rev. 2006, 58:1655-1670.
79. Shalviri A., Raval G., Prasad P., Chan C., Liu Q., Heerklotz H., et al. pH-Dependent doxorubicin release from terpolymer of starch, polymethacrylic acid and polysorbate 80 nanoparticles for overcoming multi-drug resistance in human breast cancer cells. Eur. J. Pharm. Biopharm. 2012, 82:587-597.
80. Hamaguchi T., Matsumura Y., Suzuki M., Shimizu K., Goda R., Nakamura I., et al. NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br. J. Cancer 2005, 92:1240-1246.
81. Kato K., Chin K., Yoshikawa T., Yamaguchi K., Tsuji Y., Esaki T., et al. Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer. Investig. New Drugs 2012, 30:1621-1627.
82. Matsumura Y. The drug discovery by nanomedicine and its clinical experience. Jpn. J. Clin. Oncol. 2014, 44:515-525.
83. Park S.Y., Bae Y.H. Novel pH-sensitive polymers containing sulfonamide groups. Macromol. Rapid Commun. 1999, 20:269-273.
84. Sethuraman V.A., Lee M.C., Bae Y.H. A biodegradable pH-sensitive micelle system for targeting acidic solid tumors. Pharm. Res. 2008, 25:657-666.
85. Ravazzolo E., Salmaso S., Mastrotto F., Bersani S., Gallon E., Caliceti P. pH-responsive lipid core micelles for tumour targeting. Eur. J. Pharm. Biopharm. 2013, 83:346-357.
86. Taghizadeh B., Taranejoo S., Monemian S.A., Salehi Moghaddam Z., Daliri K., Derakhshankhah H., et al. Classification of stimuli-responsive polymers as anticancer drug delivery systems. Drug Deliv. 2014, 1-11.
87. Verbaan F.J., Klouwenberg P.K., Steenis J.H.v., Snel C.J., Boerman O., Hennink W.E., et al. Application of poly(2-(dimethylamino)ethyl methacrylate)-based polyplexes for gene transfer into human ovarian carcinoma cells. Int. J. Pharm. 2005, 304:185-192.
88. Chang G., Li C., Lu W., Ding J. N-Boc-histidine-capped PLGA-PEG-PLGA as a smart polymer for drug delivery sensitive to tumor extracellular pH. Macromol. Biosci. 2010, 10:1248-1256.
89. Na K., Lee E.S., Bae Y.H. Self-organized nanogels responding to tumor extracellular pH: pH-dependent drug Release and in vitro cytotoxicity against MCF-cells. Bioconjug. Chem. 2007, 18:1568-1574.
90. Johnson R.P., Jeong Y.I., John J.V., Chung C.-W., Kang D.H., Selvaraj M., et al. Dual stimuli-responsive poly(N-isopropylacrylamide)-b-poly(l-histidine) chimeric materials for the controlled delivery of doxorubicin into liver carcinoma. Biomacromolecules 2013, 14:1434-1443.
91. Hong W., Chen D., Jia L., Gu J., Hu H., Zhao X., et al. Thermo- and pH-responsive copolymers based on PLGA-PEG-PLGA and poly(L-histidine): synthesis and in vitro characterization of copolymer micelles. Acta Biomater. 2014, 10:1259-1271.
92. Lee E.S., Shin H.J., Na K., Bae Y.H. Poly(L-histidine)-PEG block copolymer micelles and pH-induced destabilization. J. Control. Release 2003, 90:363-374.
93. Wang C.Y., Huang L. Polyhistidine mediates an acid-dependent fusion of negatively charged liposomes. Biochemistry 1984, 23:4409-4416.
94. Yang S.R., Lee H.J., Kim J.-D. Histidine-conjugated poly(amino acid) derivatives for the novel endosomolytic delivery carrier of doxorubicin. J. Control. Release 2006, 114:60-68.
95. Hu J., Miura S., Na K., Bae Y.H. pH-responsive and charge shielded cationic micelle of poly(l-histidine)-block-short branched PEI for acidic cancer treatment. J. Control. Release 2013, 172:69-76.
96. Yin H., Lee E.S., Kim D., Lee K.H., Oh K.T., Bae Y.H. Physicochemical characteristics of pH-sensitive poly(l-Histidine)-b-poly(ethylene glycol)/poly(l-Lactide)-b-poly(ethylene glycol) mixed micelles. J. Control. Release 2008, 126:130-138.
97. Bechinger B. Towards membrane protein design: pH-sensitive topology of histidine-containing polypeptides. J. Mol. Biol. 1996, 263:768-775.
98. Chiang Y.-T., Cheng Y.-T., Lu C.-Y., Yen Y.-W., Yu L.-Y., Yu K.-S., et al. Polymer-liposome complexes with a functional hydrogen-bond cross-linker for preventing protein adsorption and improving tumor accumulation. Chem. Mater. 2013, 25:4364-4372.
99. Chiang Y.T., Lo C.L. pH-Responsive polymer-liposomes for intracellular drug delivery and tumor extracellular matrix switched-on targeted cancer therapy. Biomaterials 2014, 35:5414-5424.
100. Shenoy D., Little S., Langer R., Amiji M. Poly(ethylene oxide)-modified poly(β-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs. 1. In vitro evaluations. Mol. Pharm. 2005, 2:357-366.
101. Min K.H., Kim J.H., Bae S.M., Shin H., Kim M.S., Park S., et al. Tumoral acidic pH-responsive MPEG-poly(beta-amino ester) polymeric micelles for cancer targeting therapy. J. Control. Release 2010, 144:259-266.
102. Kim J., Oh Y., Lee K., Yun J., Park B., Oh K. Development of a pH-sensitive polymer using poly(aspartic acid-graft-imidazole)-block-poly(ethylene glycol) for acidic pH targeting systems. Macromol. Res. 2011, 19:453-460.
103. Liu H., Liu M., Ma L., Chen J. Thermo- and pH-sensitive comb-type grafted poly(N,N-diethylacrylamide-co-acrylic acid) hydrogels with rapid response behaviors. Eur. Polym. J. 2009, 45:2060-2067.
104. Lin Y.-L., Jiang G., Birrell L.K., El-Sayed M.E.H. Degradable, pH-sensitive, membrane-destabilizing, comb-like polymers for intracellular delivery of nucleic acids. Biomaterials 2010, 31:7150-7166.
105. Xu Q., Huang W., Jiang L., Lei Z., Li X., Deng H. KGM and PMAA based pH-sensitive interpenetrating polymer network hydrogel for controlled drug release. Carbohydr. Polym. 2013, 97:565-570.
106. Yuba E., Harada A., Sakanishi Y., Watarai S., Kono K. A liposome-based antigen delivery system using pH-sensitive fusogenic polymers for cancer immunotherapy. Biomaterials 2013, 34:3042-3052.
107. Sakaguchi N., Kojima C., Harada A., Kono K. Preparation of pH-sensitive poly(glycidol) derivatives with varying hydrophobicities: their ability to sensitize stable liposomes to pH. Bioconjug. Chem. 2008, 19:1040-1048.
108. Kim M.S., Hwang S.J., Han J.K., Choi E.K., Park H.J., Kim J.S., et al. pH-Responsive PEG-Poly(β-amino ester) block copolymer micelles with a sharp transition. Macromol. Rapid Commun. 2006, 27:447-451.
109. Kim E.J., Cho S.H., Yuk S.H. Polymeric microspheres composed of pH/temperature-sensitive polymer complex. Biomaterials 2001, 22:2495-2499.
110. Hu Y., Wang J., Zhang H., Jiang G., Kan C. Synthesis and characterization of monodispersed P(St-co-DMAEMA) nanoparticles as pH-sensitive drug delivery system. Mater. Sci. Eng. 2014, 45:1-7.
111. Wu W., Liu J., Cao S., Tan H., Li J., Xu F., et al. Drug release behaviors of a pH sensitive semi-interpenetrating polymer network hydrogel composed of poly(vinyl alcohol) and star poly[2-(dimethylamino)ethyl methacrylate]. Int. J. Pharm. 2011, 416:104-109.
112. Paliwal S.R., Paliwal R., Vyas S.P. A review of mechanistic insight and application of pH-sensitive liposomes in drug delivery. Drug Deliv. 2015, 22:231-242.
113. Hong M.S., Lim S.J., Oh Y.K., Kim C.K. pH-sensitive, serum-stable and long-circulating liposomes as a new drug delivery system. J. Pharm. Pharmacol. 2002, 54:51-58.
114. Cullis P.R., de Kruijff B. Lipid polymorphism and the functional roles of lipids in biological membranes. Biochim. Biophys. Acta 1979, 559:399-420.
115. Seddon J.M., Cevc G., Marsh D. Calorimetric studies of the gel-fluid (beta-alpha) and lamellar-inverted hexagonal (alpha-HII) phase transitions in dialkyl- and diacylphosphatidylethanolamines. Biochemistry 1983, 22:1280-1289.
116. Rostovtseva T.K., Gurnev P.A., Chen M.Y., Bezrukov S.M. Membrane lipid composition regulates tubulin interaction with mitochondrial voltage-dependent anion channel. J. Biol. Chem. 2012, 287:29589-29598.
117. Duzgunes N., Straubinger R.M., Baldwin P.A., Friend D.S., Papahadjopoulos D. Proton-induced fusion of oleic acid-phosphatidylethanolamine liposomes. Biochemistry 1985, 24:3091-3098.
118. Lai M.Z., Duzgunes N., Szoka F.C. Effects of replacement of the hydroxyl group of cholesterol and tocopherol on the thermotropic behavior of phospholipid membranes. Biochemistry 1985, 24:1646-1653.
119. Lasic D.D. Novel applications of liposomes. Trends Biotechnol. 1998, 16:307-321.
120. Leite E.A., Souza C.M., Carvalho-Junior A.D., Coelho L.G., Lana A.M., Cassali G.D., et al. Encapsulation of cisplatin in long-circulating and pH-sensitive liposomes improves its antitumor effect and reduces acute toxicity. Int. J. Nanomedicine 2012, 7:5259-5269.
121. Zhang C., Wang W., Liu T., Wu Y., Guo H., Wang P., et al. Doxorubicin-loaded glycyrrhetinic acid-modified alginate nanoparticles for liver tumor chemotherapy. Biomaterials 2012, 33:2187-2196.
122. Lv Y., Huang H., Yang B., Liu H., Li Y., Wang J. A robust pH-sensitive drug carrier: aqueous micelles mineralized by calcium phosphate based on chitosan. Carbohydr. Polym. 2014, 111:101-107.
123. Zhou Y.Y., Du Y.Z., Wang L., Yuan H., Zhou J.P., Hu F.Q. Preparation and pharmacodynamics of stearic acid and poly (lactic-co-glycolic acid) grafted chitosan oligosaccharide micelles for 10-hydroxycamptothecin. Int. J. Pharm. 2010, 393:143-151.
124. Liu J., Li H., Chen D., Jin X., Zhao X., Zhang C., et al. In vivo evaluation of novel chitosan graft polymeric micelles for delivery of paclitaxel. Drug Deliv. 2011, 18:181-189.
125. Wang M., Hu H., Sun Y., Qiu L., Zhang J., Guan G., et al. A pH-sensitive gene delivery system based on folic acid-PEG-chitosan - PAMAM-plasmid DNA complexes for cancer cell targeting. Biomaterials 2013, 34:10120-10132.
126. Yan L., Crayton S.H., Thawani J.P., Amirshaghaghi A., Tsourkas A., Cheng Z. A pH-responsive drug-delivery platform based on glycol chitosan-coated liposomes. Small 2015, 11:4870-4874.
127. Saravanakumar G., Park J.H., Kim K., Kwon I.C. Polysaccharide-based Drug Conjugates for Tumor Targeting. Drug Delivery in Oncology 2011, 701-746. Wiley-VCH Verlag GmbH & Co. KGaA.
128. Jiang T., Zhang Z., Zhang Y., Lv H., Zhou J., Li C., et al. Dual-functional liposomes based on pH-responsive cell-penetrating peptide and hyaluronic acid for tumor-targeted anticancer drug delivery. Biomaterials 2012, 33:9246-9258.
129. Ouahab A., Cheraga N., Onoja V., Shen Y., Tu J. Novel pH-sensitive charge-reversal cell penetrating peptide conjugated PEG-PLA micelles for docetaxel delivery: in vitro study. Int. J. Pharm. 2014, 466:233-245.
130. Subbarao N.K., Parente R.A., Szoka F.C., Nadasdi L., Pongracz K. pH-dependent bilayer destabilization by an amphipathic peptide. Biochemistry 1987, 26:2964-2972.
131. Wyman T.B., Nicol F., Zelphati O., Scaria P.V., Plank C., Szoka F.C. Design, synthesis, and characterization of a cationic peptide that binds to nucleic acids and permeabilizes bilayers. Biochemistry 1997, 36:3008-3017.
132. Guo X.D., Wiradharma N., Liu S.Q., Zhang L.J., Khan M., Qian Y., et al. Oligomerized alpha-helical KALA peptides with pendant arms bearing cell-adhesion, DNA-binding and endosome-buffering domains as efficient gene transfection vectors. Biomaterials 2012, 33:6284-6291.
133. Vogel K., Wang S., Lee R.J., Chmielewski J., Low P.S. Peptide-mediated release of folate-targeted liposome contents from endosomal compartments. J. Am. Chem. Soc. 1996, 118:1581-1586.
134. Nakamura T., Akita H., Yamada Y., Hatakeyama H., Harashima H. A multifunctional envelope-type nanodevice for use in nanomedicine: concept and applications. Acc. Chem. Res. 2012, 45:1113-1121.
135. Sakurai Y., Hatakeyama H., Sato Y., Akita H., Takayama K., Kobayashi S., et al. Endosomal escape and the knockdown efficiency of liposomal-siRNA by the fusogenic peptide shGALA. Biomaterials 2011, 32:5733-5742.
136. Mahato R., Tai W., Cheng K. Prodrugs for improving tumor targetability and efficiency. Adv. Drug Deliv. Rev. 2011, 63:659-670.
137. Tang R., Ji W., Panus D., Palumbo R.N., Wang C. Block copolymer micelles with acid-labile ortho ester side-chains: synthesis, characterization, and enhanced drug delivery to human glioma cells. J. Control. Release 2011, 151:18-27.
138. Sun T.M., Wang Y.C., Wang F., Du J.Z., Mao C.Q., Sun C.Y., et al. Cancer stem cell therapy using doxorubicin conjugated to gold nanoparticles via hydrazone bonds. Biomaterials 2014, 35:836-845.
139. Gillies E.R., Frechet J.M. pH-Responsive copolymer assemblies for controlled release of doxorubicin. Bioconjug. Chem. 2005, 16:361-368.
140. Shin J., Shum P., Grey J., Fujiwara S.-I., Malhotra G.S., González-Bonet A., et al. Acid-labile mPEG-vinyl ether-1,2-dioleylglycerol lipids with tunable pH sensitivity: synthesis and structural effects on hydrolysis rates, DOPE liposome release performance, and pharmacokinetics. Mol. Pharm. 2012, 9:3266-3276.
141. Shin J., Shum P., Thompson D.H. Acid-triggered release via dePEGylation of DOPE liposomes containing acid-labile vinyl ether PEG-lipids. J. Control. Release 2003, 91:187-200.
142. Kim H.-K., Van den Bossche J., Hyun S.-H., Thompson D.H. Acid-triggered release via dePEGylation of fusogenic liposomes mediated by heterobifunctional phenyl-substituted vinyl ethers with tunable pH-sensitivity. Bioconjug. Chem. 2012, 23:2071-2077.
143. Kale A.A., Torchilin V.P. "Smart" drug carriers: PEGylated TATp-modified pH-sensitive liposomes. J. Liposome Res. 2007, 17:197-203.
144. Etrych T., Subr V., Laga R., Rihova B., Ulbrich K. Polymer conjugates of doxorubicin bound through an amide and hydrazone bond: impact of the carrier structure onto synergistic action in the treatment of solid tumours. Eur. J. Pharm. Sci. 2014, 58:1-12.
145. Prabaharan M., Grailer J.J., Pilla S., Steeber D.A., Gong S. Amphiphilic multi-arm-block copolymer conjugated with doxorubicin via pH-sensitive hydrazone bond for tumor-targeted drug delivery. Biomaterials 2009, 30:5757-5766.
146. Shi J., Liu Y., Wang L., Gao J., Zhang J., Yu X., et al. A tumoral acidic pH-responsive drug delivery system based on a novel photosensitizer (fullerene) for in vitro and in vivo chemo-photodynamic therapy. Acta Biomater. 2014, 10:1280-1291.
147. Nakamura H., Etrych T., Chytil P., Ohkubo M., Fang J., Ulbrich K., et al. Two step mechanisms of tumor selective delivery of N-(2-hydroxypropyl)methacrylamide copolymer conjugated with pirarubicin via an acid-cleavable linkage. J. Control. Release 2014, 174:81-87.
148. Alani A.W.G., Bae Y., Rao D.A., Kwon G.S. Polymeric micelles for the pH-dependent controlled, continuous low dose release of paclitaxel. Biomaterials 2010, 31:1765-1772.
149. Rodrigues P.C.A., Scheuermann K., Stockmar C., Maier G., Fiebig H.H., Unger C., et al. Synthesis and in vitro efficacy of acid-sensitive poly(ethylene glycol) paclitaxel conjugates. Bioorg. Med. Chem. Lett. 2003, 13:355-360.
150. Sawant R.R., Torchilin V.P. Enhanced cytotoxicity of TATp-bearing paclitaxel-loaded micelles in vitro and in vivo. Int. J. Pharm. 2009, 374:114-118.
151. Hami Z., Amini M., Ghazi-Khansari M., Rezayat S.M., Gilani K. Synthesis and in vitro evaluation of a pH-sensitive PLA-PEG-folate based polymeric micelle for controlled delivery of docetaxel. Colloids Surf. B Biointerfaces 2014, 116:309-317.
152. Dhar S., Gu F.X., Langer R., Farokhza O.C., Lippard S.J. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA - PEG nanoparticles. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:17356-17361.
153. Howard M.D., Ponta A., Eckman A., Jay M., Bae Y. Polymer micelles with hydrazone-ester dual linkers for tunable release of dexamethasone. Pharm. Res. 2011, 28:2435-2446.
154. Kostková H., Etrych T., Říhová B., Kostka L., Starovoytová L., Kovář M., et al. HPMA copolymer conjugates of DOX and mitomycin C for combination therapy: physicochemical characterization, cytotoxic effects, combination index analysis, and anti-tumor efficacy. Macromol. Biosci. 2013, 13:1648-1660.
155. Chen D., Sun K., Mu H., Tang M., Liang R., Wang A., et al. pH and temperature dual-sensitive liposome gel based on novel cleavable mPEG-Hz-CHEMS polymeric vaginal delivery system. Int. J. Nanomedicine 2012, 7:2621-2630.
156. Chen D., Liu W., Shen Y., Mu H., Zhang Y., Liang R., et al. Effects of a novel pH-sensitive liposome with cleavable esterase-catalyzed and pH-responsive double smart mPEG lipid derivative on ABC phenomenon. Int. J. Nanomedicine 2011, 6:2053-2061.
157. Lebrecht D., Geist A., Ketelsen U.P., Haberstroh J., Setzer B., Kratz F., et al. The 6-maleimidocaproyl hydrazone derivative of doxorubicin (DOXO-EMCH) is superior to free doxorubicin with respect to cardiotoxicity and mitochondrial damage. Int. J. Cancer 2007, 120:927-934.
158. Kratz F. DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials. Expert Opin. Investig. Drugs 2007, 16:855-866.
159. Cobo I., Li M., Sumerlin B.S., Perrier S. Smart hybrid materials by conjugation of responsive polymers to biomacromolecules. Nat. Mater. 2015, 14:143-159.
160. Hoffmann S., Vystrcilova L., Ulbrich K., Etrych T., Caysa H., Mueller T., et al. Dual fluorescent HPMA copolymers for passive tumor targeting with pH-sensitive drug release: synthesis and characterization of distribution and tumor accumulation in mice by noninvasive multispectral optical imaging. Biomacromolecules 2012, 13:652-663.
161. Chytil P., Hoffmann S., Schindler L., Kostka L., Ulbrich K., Caysa H., et al. Dual fluorescent HPMA copolymers for passive tumor targeting with pH-sensitive drug release II: impact of release rate on biodistribution. J. Control. Release 2013, 172:504-512.
162. Zhou Z., Li L., Yang Y., Xu X., Huang Y. Tumor targeting by pH-sensitive, biodegradable, cross-linked N-(2-hydroxypropyl) methacrylamide copolymer micelles. Biomaterials 2014, 35:6622-6635.
163. Takahashi A., Yamamoto Y., Yasunaga M., Koga Y., Kuroda J., Takigahira M., et al. NC-6300, an epirubicin-incorporating micelle, extends the antitumor effect and reduces the cardiotoxicity of epirubicin. Cancer Sci. 2013, 104:920-925.
164. Harada M., Bobe I., Saito H., Shibata N., Tanaka R., Hayashi T., et al. Improved anti-tumor activity of stabilized anthracycline polymeric micelle formulation, NC-6300. Cancer Sci. 2011, 102:192-199.
165. Pu Y., Chang S., Yuan H., Wang G., He B., Gu Z. The anti-tumor efficiency of poly(L-glutamic acid) dendrimers with polyhedral oligomeric silsesquioxane cores. Biomaterials 2013, 34:3658-3666.
166. Sun T.-M., Wang Y.-C., Wang F., Du J.-Z., Mao C.-Q., Sun C.-Y., et al. Cancer stem cell therapy using doxorubicin conjugated to gold nanoparticles via hydrazone bonds. Biomaterials 2014, 35:836-845.
167. Ding C., Gu J., Qu X., Yang Z. Preparation of multifunctional drug carrier for tumor-specific uptake and enhanced intracellular delivery through the conjugation of weak acid labile linker. Bioconjug. Chem. 2009, 20:1163-1170.
168. Wang C., Wang G., Wang Z., Zhang X. A pH-responsive superamphiphile based on dynamic covalent bonds. Chem. Eur. J. 2011, 17:3322-3325.
169. Jain N.K., Tare M.S., Mishra V., Tripathi P.K. The development, characterization and in vivo anti-ovarian cancer activity of poly(propylene imine) (PPI)-antibody conjugates containing encapsulated paclitaxel. Nanomed. Nanotechnol. Biol. Med. 2015, 11:207-218.
170. Yang K., Wei H., Ying-Qian L., Yuan M., Min-Min F., Li-Sheng D., et al. pH-responsive polymer-drug conjugates as multifunctional micelles for cancer-drug delivery. Nanotechnology 2014, 25:335101.
171. Szabó I., Manea M., Orbán E., Csámpai A., Bosze S., Szabó R., et al. Development of an oxime bond containing daunorubicin-gonadotropin-releasing hormone-iii conjugate as a potential anticancer drug. Bioconjug. Chem. 2009, 20:656-665.
172. Jin Y., Song L., Su Y., Zhu L., Pang Y., Qiu F., et al. Oxime linkage: a robust tool for the design of pH-sensitive polymeric drug carriers. Biomacromolecules 2011, 12:3460-3468.
173. Zloh M., Dinand E., Brocchini S. Aconityl-derived polymers for biomedical applications. Modeling study of cis-trans isomerisation. Theor. Chem. Acc. 2003, 109:206-212.
174. Shen W.-C., Ryser H.J.P. Cis-aconityl spacer between daunomycin and macromolecular carriers: a model of pH-sensitive linkage releasing drug from a lysosomotropic conjugate. Biochem. Biophys. Res. Commun. 1981, 102:1048-1054.
175. Dinand E., Zloh M., Brocchini S. Competitive reactions during amine addition to cis-Aconityl anhydride. Aust. J. Chem. 2002, 55:467-474.
176. Chytil P., Etrych T., Koňák Č., Šírová M., Mrkvan T., Říhová B., et al. Properties of HPMA copolymer-doxorubicin conjugates with pH-controlled activation: effect of polymer chain modification. J. Control. Release 2006, 115:26-36.
177. Kakinoki A., Kaneo Y., Ikeda Y., Tanaka T., Fujita K. Synthesis of poly(vinyl alcohol)-doxorubicin conjugates containing cis-aconityl acid-cleavable bond and its isomer dependent doxorubicin release. Biol. Pharm. Bull. 2008, 31:103-110.
178. Yoo H.S., Lee E.A., Park T.G. Doxorubicin-conjugated biodegradable polymeric micelles having acid-cleavable linkages. J. Control. Release 2002, 82:17-27.
179. Zhu S., Hong M., Tang G., Qian L., Lin J., Jiang Y., et al. Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxorubicin: the effects of PEGylation degree and drug conjugation style. Biomaterials 2010, 31:1360-1371.
180. Gillies E.R., Goodwin A.P., Fréchet J.M.J. Acetals as pH-sensitive linkages for drug delivery. Bioconjug. Chem. 2004, 15:1254-1263.
181. Carmali S., Brocchini S. Chapter 13-polyacetals. Natural and Synthetic Biomedical Polymers 2014, 219-233. Elsevier, Oxford. S.G. Kumbar, C.T. Laurencin, M. Deng (Eds.).
182. Kochhar K.S., Bal B.S., Deshpande R.P., Rajadhyaksha S.N., Pinnick H.W. Protecting groups in organic synthesis. Part 8. Conversion of aldehydes into geminal diacetates. J. Org. Chem. 1983, 48:1765-1767.
183. Heller J., Penhale D.W.H., Helwing R.F. Preparation of polyacetals by the reaction of divinyl ethers and polyols. J. Polym. Sci. 1980, 18:293-297.
184. Tomlinson R., Heller J., Brocchini S., Duncan R. Polyacetal-doxorubicin conjugates designed for ph-dependent degradation. Bioconjug. Chem. 2003, 14:1096-1106.
185. Wu Y., Chen W., Meng F., Wang Z., Cheng R., Deng C., et al. Core-crosslinked pH-sensitive degradable micelles: a promising approach to resolve the extracellular stability versus intracellular drug release dilemma. J. Control. Release 2012, 164:338-345.
186. Heffernan M.J., Murthy N. Polyketal nanoparticles: a new pH-sensitive biodegradable drug delivery vehicle. Bioconjug. Chem. 2005, 16:1340-1342.
187. Lin S., Du F., Wang Y., Ji S., Liang D., Yu L., et al. An acid-labile block copolymer of PDMAEMA and PEG as potential carrier for intelligent gene delivery systems. Biomacromolecules 2008, 9:109-115.
188. Chen D., Wang H. Novel pH-sensitive biodegradable polymeric drug delivery systems based on ketal polymers. J. Nanosci. Nanotechnol. 2014, 14:983-989.
189. Boomer J.A., Qualls M.M., Inerowicz H.D., Haynes R.H., Patri V.S., Kim J.-M., et al. Cytoplasmic delivery of liposomal contents mediated by an acid-labile cholesterol-vinyl ether-PEG conjugate. Bioconjug. Chem. 2009, 20:47-59.
190. Kim H.-K., Thompson D.H., Jang H.S., Chung Y.J., Van den Bossche J. pH-Responsive biodegradable assemblies containing tunable phenyl-substituted vinyl ethers for use as efficient gene delivery vehicles. ACS Appl. Mater. Interfaces 2013, 5:5648-5658.
191. Heller J. Poly (ortho esters). Biopolymers I 1993, 41-92. Springer, Berlin Heidelberg. R. Langer, N. Peppas (Eds.).
192. Masson C., Garinot M., Mignet N., Wetzer B., Mailhe P., Scherman D., et al. pH-sensitive PEG lipids containing orthoester linkers: new potential tools for nonviral gene delivery. J. Control. Release 2004, 99:423-434.
193. Nathalie M., Mamonjy C., Michel B., Daniel S. Incorporation of Poly(ethylene glycol )Lipid into Lipoplexes. Liposome Technology 2006, vol. II:273-292. Informa Healthcare.
194. Guo X., Szoka F.C. Steric stabilization of fusogenic liposomes by a low-pH sensitive PEG-diortho ester-lipid conjugate. Bioconjug. Chem. 2001, 12:291-300.
195. Huang Z., Guo X., Li W., MacKay J.A., Szoka F.C. Acid-triggered transformation of diortho ester phosphocholine liposome. J. Am. Chem. Soc. 2006, 128:60-61.
196. Guo X., Andrew MacKay J., Szoka F.C. Mechanism of pH-triggered collapse of phosphatidylethanolamine liposomes stabilized by an ortho ester polyethyleneglycol lipid. Biophys. J. 2003, 84:1784-1795.
197. Luo S., Tao Y., Tang R., Wang R., Ji W., Wang C., et al. Amphiphilic block copolymers bearing six-membered ortho ester ring in side chains as potential drug carriers: synthesis, characterization, and in vivo toxicity evaluation. J. Biomater. Sci. Polym. Ed. 2014, 25:965-984.
198. Thambi T., Deepagan V.G., Yoo C.K., Park J.H. Synthesis and physicochemical characterization of amphiphilic block copolymers bearing acid-sensitive orthoester linkage as the drug carrier. Polymer 2011, 52:4753-4759.
199. Chen H., Zhang H., Thor D., Rahimian R., Guo X. Novel pH-sensitive cationic lipids with linear ortho ester linkers for gene delivery. Eur. J. Med. Chem. 2012, 52:159-172.
200. Deslongchamps P., Dory Y.L., Li S. The relative rate of hydrolysis of a series of acyclic and six-membered cyclic acetals, ketals, orthoesters, and orthocarbonates. Tetrahedron 2000, 56:3533-3537.
201. Heller J., Barr J., Ng S.Y., Abdellauoi K.S., Gurny R. Poly(ortho esters): synthesis, characterization, properties and uses. Adv. Drug Deliv. Rev. 2002, 54:1015-1039.
202. Heller J., Barr J. Poly(ortho esters) - from concept to reality. Biomacromolecules 2004, 5:1625-1632.
203. Tang R., Ji W., Wang C. Synthesis and characterization of new poly(ortho ester amidine) copolymers for nonviral gene delivery. Polymer 2011, 52:921-932.
204. Li R., Feng F., Wang Y., Yang X., Yang X., Yang V.C. Folic acid-conjugated pH/temperature/redox multi-stimuli responsive polymer microspheres for delivery of anti-cancer drug. J. Colloid Interface Sci. 2014, 429:34-44.
205. Sadighian S., Rostamizadeh K., Hosseini-Monfared H., Hamidi M. Doxorubicin-conjugated core-shell magnetite nanoparticles as dual-targeting carriers for anticancer drug delivery. Colloids Surf. B Biointerfaces 2014, 117:406-413.
206. Wike-Hooley J.L., van den Berg A.P., van der Zee J., Reinhold H.S. Human tumour pH and its variation. Eur. J. Cancer Clin. Oncol. 1985, 21:785-791.
207. Estrella V., Chen T., Lloyd M., Wojtkowiak J., Cornnell H.H., Ibrahim-Hashim A., et al. Acidity generated by the tumor microenvironment drives local invasion. Cancer Res. 2013, 73:1524-1535.
208. Martin N.K., Robey I.F., Gaffney E.A., Gillies R.J., Gatenby R.A., Maini P.K. Predicting the safety and efficacy of buffer therapy to raise tumour pHe: an integrative modelling study. Br. J. Cancer 2012, 106:1280-1287.
209. Gerweck L.E., Vijayappa S., Kozin S. Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics. Mol. Cancer Ther. 2006, 5:1275-1279.